Statin Use and Risk of Joint Replacement: A Propensity Score Matched Cohort Study
A. Sarmanova,M. Doherty,C. Kuo,J. Wei,A. Abhishek,C. Mallen,C. Zeng,Y. Wang,G. Lei,W. Zhang
DOI: https://doi.org/10.1016/j.joca.2019.02.111
IF: 7.507
2019-01-01
Osteoarthritis and Cartilage
Abstract:Purpose: There is growing interest in statins as potential disease-modifying agents for osteoarthritis (OA) and other arthropathies such as rheumatoid arthritis (RA), but its beneficial effects remain controversial. This study aimed to examine the long-term effects of statin use on knee or hip joint replacement. Methods: The Clinical Practice Research Datalink (CPRD) is a large, longitudinal population-based, primary care database in the UK that includes data on demographics, symptoms, tests, diagnoses, prescriptions and referrals to secondary care routinely collected by general practitioners (GPs). From CPRD we selected people who were prescribed statins (i.e. statin-users) and people never prescribed statins (i.e. non-users). Each statin-user was matched with a non-user by age, gender, practice and propensity score for statin prescription. The effect of statins on risk of joint replacement (joint-specific, stratified by disease) was assessed using Cox proportional hazard regression. Statin exposure was categorised as low (21-28% reduction in low-density lipoprotein), medium (32-38%) and high (42-55%). OA was defined according to Read codes recorded by the patient's GP from the medical records including hip OA, knee OA, generalised OA, other joint OA. RA was defined according to an algorithm validated in the CPRD. Joint replacement was defined as at least one record of total or partial knee or hip joint replacement Results: 178,467 statin-users were matched to 178,467 non-users (women 52%; mean age, follow-up time, and duration of statin prescription of 62, 6.5, and 5.7 years respectively). Statin at the high dose was associated with lower risk of any joint replacement (HR 0.86, 95%CI 0.75 to 0.98), joint replacement due to RA (0.10, 0.02 to 0.65) and joint replacement due to OA (0.79, 0.68 to 0.92). The effect was in general dose-dependent but only significant for any joint replacement and knee replacement outcomes (Figure 1). However, statin at any dose was only associated with lower risk of joint replacement due to RA (HR 0.77, 0.63 to 0.94), but not due to OA (0.97, 0.94 to 1.01). Conclusions: Statins at high dose may have long-term beneficial effects on risk of hip or knee replacement. The effect may be clinically significant in people with RA. Further studies to investigate mechanisms of joint replacement risk reduction and its clinical impact in people with RA are warranted.